Related references
Note: Only part of the references are listed.Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study
Bei Yang et al.
JOURNAL OF MOLECULAR MODELING (2015)
A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity
Xinghao Ai et al.
AMINO ACIDS (2014)
Targeting EGFR mutants with non-cognate kinase inhibitors in non-small cell lung cancer
Bo Wang et al.
MEDICINAL CHEMISTRY RESEARCH (2014)
Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients
T. Doi et al.
BRITISH JOURNAL OF CANCER (2012)
Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials
Fausto Petrelli et al.
CLINICAL LUNG CANCER (2012)
Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains
Chenguang Li et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu
J. De Greve et al.
LUNG CANCER (2012)
Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein
Kathleen Aertgeerts et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Lung Cancer: Are we up to the Challenge?
Luca Esposito et al.
CURRENT GENOMICS (2010)
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Young Lim Choi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Third-Generation Tyrosine Kinase Inhibitors and Beyond
Alfonso Quintas-Cardama et al.
SEMINARS IN HEMATOLOGY (2010)
HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy
Samanthi A. Perera et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib
Tona M. Gilmer et al.
CANCER RESEARCH (2008)
Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells
Hwang-Phill Kim et al.
MOLECULAR CANCER THERAPEUTICS (2008)
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors
Shizhen Emily Wang et al.
CANCER CELL (2006)
The Amber biomolecular simulation programs
DA Case et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2005)
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas
H Shigematsu et al.
CANCER RESEARCH (2005)
Development and testing of a general amber force field
JM Wang et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2004)
Dual kinase inhibition in the treatment of breast cancer: Initial experience with the EGFR/ErbB-2 inhibitor lapatinib
HA Burris
ONCOLOGIST (2004)
Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models
PA Kollman et al.
ACCOUNTS OF CHEMICAL RESEARCH (2000)
The Protein Data Bank
HM Berman et al.
NUCLEIC ACIDS RESEARCH (2000)
Share Paper
